Aclaris Therapeutics, Inc. (ACRS)
4.39
-0.02
(-0.45%)
USD |
NASDAQ |
Oct 02, 16:00
4.395
0.00 (0.00%)
After-Hours: 20:00
Aclaris Therapeutics Gross Profit Margin (Quarterly) : 10.80% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 10.80% |
| March 31, 2026 | 10.42% |
| December 31, 2025 | -13.44% |
| September 30, 2025 | 25.77% |
| June 30, 2025 | -4.11% |
| March 31, 2025 | -4.19% |
| December 31, 2024 | -0.98% |
| September 30, 2024 | 44.59% |
| June 30, 2024 | 30.98% |
| March 31, 2024 | 23.27% |
| December 31, 2023 | 63.41% |
| September 30, 2023 | 90.86% |
| June 30, 2023 | 44.25% |
| March 31, 2023 | 68.04% |
| December 31, 2022 | 80.47% |
| September 30, 2022 | 95.15% |
| June 30, 2022 | 30.10% |
| March 31, 2022 | 20.51% |
| Date | Value |
|---|---|
| December 31, 2021 | 23.45% |
| September 30, 2021 | 33.76% |
| June 30, 2021 | 30.76% |
| March 31, 2021 | 32.36% |
| December 31, 2020 | 18.61% |
| September 30, 2020 | 17.94% |
| June 30, 2020 | 32.11% |
| March 31, 2020 | 9.81% |
| December 31, 2019 | 6.12% |
| September 30, 2019 | 15.97% |
| June 30, 2019 | -12.19% |
| March 31, 2019 | -171.8% |
| December 31, 2018 | 28.56% |
| September 30, 2018 | 4.56% |
| June 30, 2018 | 67.87% |
| March 31, 2018 | 13.51% |
| December 31, 2017 | 24.52% |
| September 30, 2017 | 33.77% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 98.41% |
| Xeris Biopharma Holdings, Inc. | 83.47% |
| Alumis, Inc. | 47.41% |
| ANI Pharmaceuticals, Inc. | 54.97% |
| Veru, Inc. | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -60.77% |
| Return on Assets | -41.91% |
| Return on Invested Capital | -59.76% |
| Profit Margin (Quarterly) | -1.32K% |
| Operating Margin (Quarterly) | -1.47K% |
| Return on Net Operating Assets | -1.03K% |